Baillie Gifford & Co
EW icon

Baillie Gifford & Co’s Edwards Lifesciences EW Stock Holding History

Baillie Gifford & Co’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109M Buy
1,208,945
+768,737
+175% +$64.4M 0.1% 129
2026
Q1 		$35.3M Sell
440,208
-76,103
-15% -$6.27M 0.04% 161
2025
Q4 		$44M Sell
516,311
-55,936
-10% -$4.59M 0.04% 154
2025
Q3 		$44.5M Sell
572,247
-10,351
-2% -$809K 0.03% 161
2025
Q2 		$45.6M Buy
582,598
+1,157
+0.2% +$86.3K 0.03% 154
2025
Q1 		$42.1M Sell
581,441
-125,355
-18% -$8.97M 0.04% 150
2024
Q4 		$52.3M Buy
706,796
+498,100
+239% +$34.9M 0.04% 143
2024
Q3 		$13.8M Sell
208,696
-143,607
-41% -$10.4M 0.01% 197
2024
Q2 		$32.5M Sell
352,303
-44,250
-11% -$3.92M 0.03% 159
2024
Q1 		$37.9M Sell
396,553
-7,405
-2% -$622K 0.03% 162
2023
Q4 		$30.8M Sell
403,958
-36,443
-8% -$2.54M 0.02% 175
2023
Q3 		$30.5M Sell
440,401
-23,639
-5% -$1.9M 0.03% 169
2023
Q2 		$43.8M Sell
464,040
-3,444
-0.7% -$299K 0.04% 158
2023
Q1 		$38.7M Buy
467,484
+31,993
+7% +$2.51M 0.03% 158
2022
Q4 		$32.5M Buy
435,491
+3,345
+0.8% +$258K 0.03% 166
2022
Q3 		$35.7M Buy
432,146
+11,921
+3% +$1.15M 0.04% 158
2022
Q2 		$40M Sell
420,225
-5,000
-1% -$518K 0.04% 164
2022
Q1 		$50.1M Sell
425,225
-7,463
-2% -$837K 0.04% 174
2021
Q4 		$56.1M Buy
432,688
+11,143
+3% +$1.3M 0.03% 176
2021
Q3 		$47.7M Buy
421,545
+17,758
+4% +$2.03M 0.03% 186
2021
Q2 		$41.8M Sell
403,787
-1,170
-0.3% -$110K 0.02% 200
2021
Q1 		$33.9M Buy
404,957
+124,646
+44% +$10.5M 0.02% 204
2020
Q4 		$25.6M Buy
280,311
+26,830
+11% +$2.23M 0.01% 190
2020
Q3 		$20.2M Buy
253,481
+58,738
+30% +$4.58M 0.01% 182
2020
Q2 		$13.5M Buy
194,743
+191,332
+5,609% +$13.6M 0.01% 186
2020
Q1 		$214K Sell
3,411
-357
-9% -$25.7K ﹤0.01% 211
2019
Q4 		$293K Hold
3,768
– – ﹤0.01% 212
2019
Q3 		$276K Sell
3,768
-213
-5% -$15K ﹤0.01% 213
2019
Q2 		$245K Hold
3,981
– – ﹤0.01% 220
2019
Q1 		$254K Hold
3,981
– – ﹤0.01% 220
2018
Q4 		$203K Buy
+3,981
New +$201K ﹤0.01% 219

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Baillie Gifford & Co's EW Position: Q2 2026 in Review

Baillie Gifford & Co increased its Edwards Lifesciences (EW) stake by 175% in Q2 2026, buying an estimated $64.4M and bringing the position to 1,208,945 shares worth $109M. The position accounts for 0.1% of the portfolio, ranked #129.

Baillie Gifford & Co first reported a position in EW in Q4 2018 and has held it in 31 quarters since. 774 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Baillie Gifford & Co held 1,208,945 shares of Edwards Lifesciences worth $109M as of Q2 2026.
  • Baillie Gifford & Co bought 768,737 Edwards Lifesciences shares in Q2 2026, an estimated $64.4M.
  • Edwards Lifesciences made up 0.1% of Baillie Gifford & Co's portfolio in Q2 2026, its #129 holding.
  • Baillie Gifford & Co first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 31 quarters since.
  • 774 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.